Greater mechanistic understanding of the cutaneous pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review

Ogiji, ED, Aboheimed, N, Ross, K ORCID: 0000-0003-0252-1152, Voller, C, Siner, R, Jensen, RL, Jolly, CE and Carr, DF (2024) Greater mechanistic understanding of the cutaneous pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review. Current Opinion in Allergy and Clinical Immunology, 24 (4). pp. 218-227. ISSN 1528-4050

Preview

Text greater_mechanistic_understanding_of_the_cutaneous.7 (1).pdf - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Purpose of review Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are severe cutaneous adverse drug reactions (SCARs) characterized by widespread epithelial detachment and blistering, which affects the skin and mucocutaneous membranes. To date, therapeutic interventions for SJS/TEN have focused on systematic suppression of the inflammatory response using high-dose corticosteroids or intravenous immunoglobulin G (IgG), for example. No targeted therapies for SJS/TEN currently exist. Recent findings Though our understanding of the pathogenesis of SJS/TEN has advanced from both an immunological and dermatological perspective, this knowledge is yet to translate into the development of new targeted therapies. Summary Greater mechanistic insight into SJS/TEN would potentially unlock new opportunities for identifying or repurposing targeted therapies to limit or even prevent epidermal injury and blistering.

Item Type:	Article
Uncontrolled Keywords:	drug hypersensitivity; drug repurposing; pathogenesis; Stevens-Johnson syndrome; toxic epidermal necrolysis; drug hypersensitivity; drug repurposing; pathogenesis; Stevens-Johnson syndrome; toxic epidermal necrolysis; Skin; Animals; Humans; Stevens-Johnson Syndrome; Adrenal Cortex Hormones; Immunoglobulins, Intravenous; Molecular Targeted Therapy; Stevens-Johnson Syndrome; Humans; Immunoglobulins, Intravenous; Skin; Adrenal Cortex Hormones; Animals; Molecular Targeted Therapy; 1107 Immunology; Allergy
Subjects:	R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology R Medicine > RS Pharmacy and materia medica
Divisions:	Pharmacy and Biomolecular Sciences
Publisher:	Lippincott, Williams & Wilkins
Date of acceptance:	1 May 2024
Date of first compliant Open Access:	8 November 2024
Date Deposited:	08 Nov 2024 14:13
Last Modified:	03 Jul 2025 18:15
DOI or ID number:	10.1097/ACI.0000000000000993
URI:	https://researchonline.ljmu.ac.uk/id/eprint/24719

View Item